| Market Cap | 291 | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | 32.05k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -39.00% |
| Sales | 4.73M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -42.00% |
| Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -93.00% | |
| Recommedations | - | Quick Ratio | 1.40 | Shares Outstanding | 1.51M | 52W Low Chg | 52.00% |
| Insider Own | - | ROA | -1.64% | Shares Float | - | Beta | -38.97 |
| Inst Own | - | ROE | 2.85% | Shares Shorted/Prior | -/- | Price | 0.16 |
| Gross Margin | 9.09% | Profit Margin | 0.68% | Avg. Volume | 1,173 | Target Price | - |
| Oper. Margin | -6.72% | Earnings Date | - | Volume | 1 | Change | 0.00% |
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.
